← All trials
NCT04924608
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2021
- Primary completion
- Oct 24, 2024
- Completion date
- May 22, 2025
- First posted
- Jun 14, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 146
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- MerckCollaborator
- National Cancer Institute (NCI)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.